Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab in Relapsing MS (ProTEct-MS)
NCT04480307Phase 2Completed
- Sponsor
- GeNeuro
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of temelimab in relapsing-remitting multiple sclerosis (RRMS), sponsored by GeNeuro. Started Jun 2020; status: completed.
02
Drugs
temelimab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04480307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480307.